(Q28242623)

1

0 references

C Elizabeth Caldon

2

0 references

Jane Barraclough

3

0 references

Andrew Stone

4

0 references

Robert L Sutherland

Living with or without cyclins and cyclin-dependent kinases

5

0 references

language of work or name

English

0 references

publication date

7 July 2011

0 references

published in

Nature Reviews Cancer

0 references

volume

11

0 references

issue

8

0 references

page(s)

558-72

0 references

cites work

1 reference

CDK inhibitors: cell cycle regulators and beyond

21 January 2018

1 reference

Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins

21 January 2018

1 reference

Identification of G1 kinase activity for cdk6, a novel cyclin D partner

21 January 2018

1 reference

Cyclins: roles in mitogenic signaling and oncogenic transformation

21 January 2018

1 reference

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

Cell cycle, CDKs and cancer: a changing paradigm

21 January 2018

1 reference

Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all.

21 January 2018

1 reference

Emerging roles of E2Fs in cancer: an exit from cell cycle control

21 January 2018

1 reference

DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1

21 January 2018

1 reference

Cyclin-dependent kinases regulate the antiproliferative function of Smads

21 January 2018

1 reference

Cyclin D1-cdk4 induce runx2 ubiquitination and degradation

21 January 2018

1 reference

Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation

21 January 2018

1 reference

Coordinated regulation of differentiation and proliferation of embryonic cardiomyocytes by a jumonji (Jarid2)-cyclin D1 pathway.

21 January 2018

1 reference

Cyclin D-cdk4 activity modulates the subnuclear localization and interaction of MEF2 with SRC-family coactivators during skeletal muscle differentiation

21 January 2018

1 reference

Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells

21 January 2018

1 reference

Cdk2 and Cdk4 regulate the centrosome cycle and are critical mediators of centrosome amplification in p53-null cells.

21 January 2018

1 reference

Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function

21 January 2018

1 reference

Negative regulation of TSC1-TSC2 by mammalian D-type cyclins.

21 January 2018

1 reference

Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase

21 January 2018

1 reference

Methylation of ribosomal protein S10 by protein-arginine methyltransferase 5 regulates ribosome biogenesis

21 January 2018

1 reference

Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells

21 January 2018

1 reference

Cyclin D1 governs adhesion and motility of macrophages

21 January 2018

1 reference

Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling

21 January 2018

1 reference

Cyclin D1 induction of cellular migration requires p27(KIP1).

21 January 2018

1 reference

Role of Cdk4 in lymphocyte function and allergen response

21 January 2018

1 reference

Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen.

21 January 2018

1 reference

P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor

21 January 2018

1 reference

Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment

21 January 2018

1 reference

Minireview: Cyclin D1: normal and abnormal functions

21 January 2018

1 reference

Distinct proliferative and transcriptional effects of the D-type cyclins in vivo

21 January 2018

1 reference

Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4

21 January 2018

1 reference

CDK-independent activation of estrogen receptor by cyclin D1

21 January 2018

1 reference

Cyclin D3 is a cofactor of retinoic acid receptors, modulating their activity in the presence of cellular retinoic acid-binding protein II

21 January 2018

1 reference

Cyclin D3 promotes adipogenesis through activation of peroxisome proliferator-activated receptor gamma

21 January 2018

1 reference

Cyclin D3/CDK11p58 complex is involved in the repression of androgen receptor

21 January 2018

1 reference

CDK inhibitors: positive and negative regulators of G1-phase progression

21 January 2018

1 reference

Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors?

21 January 2018

1 reference

A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers

21 January 2018

1 reference

Alternative cyclin D1 splice forms differentially regulate the DNA damage response

21 January 2018

1 reference

Mouse development and cell proliferation in the absence of D-cyclins.

21 January 2018

1 reference

Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6

21 January 2018

1 reference

Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis

21 January 2018

1 reference

Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice

21 January 2018

1 reference

Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity

21 January 2018

1 reference

Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization

21 January 2018

1 reference

Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy.

21 January 2018

1 reference

Genotoxic stress-induced cyclin D1 phosphorylation and proteolysis are required for genomic stability

21 January 2018

1 reference

DNA replication stalling attenuates tyrosine kinase signaling to suppress S phase progression.

21 January 2018

1 reference

Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication

21 January 2018

1 reference

Specific protection against breast cancers by cyclin D1 ablation

21 January 2018

1 reference

Requirement for CDK4 kinase function in breast cancer

21 January 2018

1 reference

The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer

21 January 2018

1 reference

A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis

21 January 2018

1 reference

Requirement for cyclin D3 in lymphocyte development and T cell leukemias

21 January 2018

1 reference

Cell-specific responses to loss of cyclin-dependent kinases.

21 January 2018

1 reference

Cyclin D2-cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss

21 January 2018

1 reference

Nuclear cyclin D1: an oncogenic driver in human cancer

21 January 2018

1 reference

Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation

21 January 2018

1 reference

Impact of differential cyclin D1 expression and localisation in prostate cancer

21 January 2018

1 reference

Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells

21 January 2018

1 reference

Cyclin D1 in low-dose radiation-induced adaptive resistance.

21 January 2018

1 reference

Cyclin D1: polymorphism, aberrant splicing and cancer risk

21 January 2018

1 reference

Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells

21 January 2018

1 reference

Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration

21 January 2018

1 reference

Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation

21 January 2018

1 reference

A census of amplified and overexpressed human cancer genes

21 January 2018

1 reference

Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice

21 January 2018

1 reference

Update on the molecular biology of mantle cell lymphoma

21 January 2018

1 reference

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

The landscape of somatic copy-number alteration across human cancers

21 January 2018

1 reference

Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival

21 January 2018

1 reference

Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1.

21 January 2018

1 reference

Cyclin D1 gene (CCND1) mutations in endometrial cancer

21 January 2018

1 reference

Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer

21 January 2018

1 reference

Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer

21 January 2018

1 reference

Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis

21 January 2018

1 reference

Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients.

21 January 2018

1 reference

Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome

21 January 2018

1 reference

Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer

21 January 2018

1 reference

Coupled alteration of transcription and splicing by a single oncogene: boosting the effect on cyclin D1 activity

21 January 2018

1 reference

The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2

21 January 2018

1 reference

Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway

21 January 2018

1 reference

Initiating oncogenic event determines gene-expression patterns of human breast cancer models

21 January 2018

1 reference

Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance

21 January 2018

1 reference

Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis

21 January 2018

1 reference

miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer

21 January 2018

1 reference

The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities

21 January 2018

1 reference

Systematic validation of predicted microRNAs for cyclin D1

21 January 2018

1 reference

The activities of cyclin D1 that drive tumorigenesis

21 January 2018

1 reference

Cyclin D1 in breast cancer pathogenesis

21 January 2018

1 reference

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

21 January 2018

1 reference

Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics

21 January 2018

1 reference

A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer

21 January 2018

1 reference

RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response

21 January 2018

1 reference

Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer

21 January 2018

1 reference

Cyclin D1 determines mitochondrial function in vivo

21 January 2018

1 reference

Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression

21 January 2018

1 reference

Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells

21 January 2018

1 reference

Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma

21 January 2018

1 reference

Cyclin D1 and breast cancer

21 January 2018

1 reference

Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.

21 January 2018

1 reference

Tailoring to RB: tumour suppressor status and therapeutic response

21 January 2018

1 reference

CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome

21 January 2018

1 reference

Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line

21 January 2018

1 reference

Biological determinants of endocrine resistance in breast cancer

21 January 2018

1 reference

Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines

21 January 2018

1 reference

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

21 January 2018

1 reference

The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers

21 January 2018

1 reference

Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy

21 January 2018

1 reference

Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients

21 January 2018

1 reference

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy

21 January 2018

1 reference

Cell cycle kinases as therapeutic targets for cancer

21 January 2018

1 reference

Cyclin-dependent kinase pathways as targets for cancer treatment

21 January 2018

1 reference

Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis

21 January 2018

1 reference

Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.

21 January 2018

1 reference

Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.

21 January 2018

1 reference

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

21 January 2018

1 reference

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts

21 January 2018

1 reference

Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM

21 January 2018

1 reference

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer

21 January 2018

1 reference

Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer

21 January 2018

1 reference

A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell

21 January 2018

1 reference

Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients.

21 January 2018

1 reference

Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study

21 January 2018

1 reference

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).

21 January 2018

1 reference

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

21 January 2018

1 reference

Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.

21 January 2018

1 reference

Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo.

21 January 2018

1 reference

A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo

21 January 2018

1 reference

Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles

21 January 2018

1 reference

Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation.

21 January 2018

1 reference

Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A.

21 January 2018

1 reference

Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors

21 January 2018

1 reference

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

Crystal structure of human CDK4 in complex with a D-type cyclin

21 January 2018

1 reference

The structure of CDK4/cyclin D3 has implications for models of CDK activation

21 January 2018

1 reference

Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer.

21 January 2018

1 reference

Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy

21 January 2018

1 reference

Bexarotene and erlotinib for aerodigestive tract cancer

21 January 2018

1 reference

Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy

21 January 2018

1 reference

The BATTLE trial: personalizing therapy for lung cancer

21 January 2018

1 reference

Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models

21 January 2018

1 reference

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention

21 January 2018

1 reference

Suppression of cancer cell growth by promoting cyclin D1 degradation

21 January 2018

1 reference

A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.

21 January 2018

1 reference

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

21 January 2018

1 reference

Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment

21 January 2018

1 reference

Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition.

21 January 2018

1 reference

A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

21 January 2018

1 reference

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

21 January 2018

1 reference

Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1

21 January 2018

1 reference

Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity

21 January 2018

1 reference

Molecular pathogenesis of head and neck squamous cell carcinoma

21 January 2018

1 reference

Molecular alterations associated with cyclin D1 overexpression in endometrial cancer

21 January 2018

1 reference

Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma.

21 January 2018

1 reference

The role of cell cycle regulatory proteins in the pathogenesis of melanoma.

21 January 2018

1 reference

Molecular prognostic markers in pancreatic cancer: a systematic review

21 January 2018

1 reference

Tissue microarray analysis of cyclin D1 gene amplification and gain in colorectal carcinomas

21 January 2018

1 reference

Molecular pathogenesis and a consequent classification of multiple myeloma

21 January 2018

1 reference

In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials

21 January 2018

1 reference

Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709.

21 January 2018

1 reference

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours

21 January 2018

1 reference

Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes

21 January 2018

1 reference

Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner

31 March 2020

1 reference

Linking cyclins to transcriptional control.

31 March 2020

1 reference

Acquired radioresistance of human tumor cells by DNA-PK/AKT/GSK3beta-mediated cyclin D1 overexpression

31 March 2020

1 reference

Tyrosine kinases as targets for cancer therapy

31 March 2020

1 reference

Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1

31 March 2020

1 reference

Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative

31 March 2020

1 reference

D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability

31 March 2020

1 reference

12 December 2020

Cyclin D1b represses breast cancer cell growth by antagonizing the action of cyclin D1a on estrogen receptor alpha-mediated transcription.

1 reference

12 December 2020

Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer

1 reference

12 December 2020

Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue

1 reference

12 December 2020

Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance

1 reference

12 December 2020

Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes.

1 reference

12 December 2020

Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues

1 reference

12 December 2020

Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation.

1 reference

12 December 2020

Formation of higher-order nuclear Rad51 structures is functionally linked to p21 expression and protection from DNA damage-induced apoptosis.

1 reference

12 December 2020

Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation

1 reference

12 December 2020

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

1 reference

12 December 2020

Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome

1 reference

12 December 2020

Somatic variation and cancer: therapies lost in the mix.

1 reference

12 December 2020

Multiple functions of D-type cyclins can antagonize pRb-mediated suppression of proliferation.

1 reference

12 December 2020